These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19811836)

  • 1. Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody.
    Dimitrov JD; Roumenina LT; Andre S; Repesse Y; Atanasov BP; Jacquemin M; Saint-Remy JM; Bayry J; Kaveri SV; Lacroix-Desmazes S
    Mol Immunol; 2009 Dec; 47(2-3):290-7. PubMed ID: 19811836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic parameters of monoclonal antibodies ESH2, ESH4, ESH5, and ESH8 on coagulation factor VIII and their influence on factor VIII activity.
    Egler C; Albert T; Brokemper O; Zabe-Kühn M; Mayer G; Oldenburg J; Schwaab R
    J Mol Recognit; 2009; 22(4):301-6. PubMed ID: 19266540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor.
    Dimitrov JD; Christophe OD; Kang J; Repessé Y; Delignat S; Kaveri SV; Lacroix-Desmazes S
    Biochemistry; 2012 May; 51(20):4108-16. PubMed ID: 22559004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody.
    Lin JC; Ettinger RA; Schuman JT; Zhang AH; Wamiq-Adhami M; Nguyen PC; Nakaya-Fletcher SM; Puranik K; Thompson AR; Pratt KP
    PLoS One; 2015; 10(1):e0116577. PubMed ID: 25615825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope.
    Dimitrov JD; Roumenina LT; Plantier JL; Andre S; Saboulard D; Meslier Y; Planchais C; Jacquemin M; Saint-Remy JM; Atanasov BP; Kaveri SV; Lacroix-Desmazes S
    J Thromb Haemost; 2010 Jul; 8(7):1524-31. PubMed ID: 20374449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
    Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
    Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab.
    Kessel C; Königs C; Linde R; Escuriola-Ettinghausen C; Stoll H; Klingebiel T; Dietrich U; Kreuz W
    Mol Immunol; 2008 Nov; 46(1):8-15. PubMed ID: 18715645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computer simulation of protein-protein association kinetics: acetylcholinesterase-fasciculin.
    Elcock AH; Gabdoulline RR; Wade RC; McCammon JA
    J Mol Biol; 1999 Aug; 291(1):149-62. PubMed ID: 10438612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody recognition of a flexible epitope at the DNA binding site of the human papillomavirus transcriptional regulator E2.
    Cerutti ML; Ferreiro DU; Sanguineti S; Goldbaum FA; de Prat-Gay G
    Biochemistry; 2006 Dec; 45(51):15520-8. PubMed ID: 17176073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations in antigen-antibody association kinetics as a function of pH and salt concentration: a QSAR and molecular modeling study.
    Dejaegere A; Choulier L; Lafont V; De Genst E; Altschuh D
    Biochemistry; 2005 Nov; 44(44):14409-18. PubMed ID: 16262241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimerization of peptide mimotopes for blocking of factor VIII neutralizing antibodies.
    Kessel C; Kreuz W; Klich K; Becker-Peters K; Vorpahl F; Dietrich U; Klingebiel T; Königs C
    ChemMedChem; 2009 Aug; 4(8):1364-70. PubMed ID: 19533722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designed ankyrin repeat proteins: a new approach to mimic complex antigens for diagnostic purposes?
    Hausammann S; Vogel M; Kremer Hovinga JA; Lacroix-Desmazes S; Stadler BM; Horn MP
    PLoS One; 2013; 8(4):e60688. PubMed ID: 23626669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial versus complete factor VIII inhibition in a mouse model of venous thrombosis.
    Emmerechts J; Vanassche T; Loyen S; Van Linthout I; Cludts K; Kauskot A; Long C; Jacquemin M; Hoylaerts MF; Verhamme P
    Thromb Res; 2012 Apr; 129(4):514-9. PubMed ID: 21777952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor.
    Bovenschen N; Rijken DC; Havekes LM; van Vlijmen BJ; Mertens K
    J Thromb Haemost; 2005 Jun; 3(6):1257-65. PubMed ID: 15946216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contributions of interfacial residues of human Interleukin15 to the specificity and affinity for its private alpha-receptor.
    Sakamoto S; Caaveiro JM; Sano E; Tanaka Y; Kudou M; Tsumoto K
    J Mol Biol; 2009 Jun; 389(5):880-94. PubMed ID: 19406127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor.
    Villard S; Lacroix-Desmazes S; Kieber-Emmons T; Piquer D; Grailly S; Benhida A; Kaveri SV; Saint-Remy JM; Granier C
    Blood; 2003 Aug; 102(3):949-52. PubMed ID: 12676786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The binding sites for the very low density lipoprotein receptor and low-density lipoprotein receptor-related protein are shared within coagulation factor VIII.
    Ananyeva NM; Makogonenko YM; Kouiavskaia DV; Ruiz J; Limburg V; Meijer AB; Khrenov AV; Shima M; Strickland DK; Saenko EL
    Blood Coagul Fibrinolysis; 2008 Mar; 19(2):166-77. PubMed ID: 18277139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody.
    Jacquemin M; Radcliffe CM; Lavend'homme R; Wormald MR; Vanderelst L; Wallays G; Dewaele J; Collen D; Vermylen J; Dwek RA; Saint-Remy JM; Rudd PM; Dewerchin M
    J Thromb Haemost; 2006 May; 4(5):1047-55. PubMed ID: 16689758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons.
    Jacquemin M; Stassen JM; Saint-Remy JM; Verhamme P; Lavend'homme R; VanderElst L; Meiring M; Pieters H; Lamprecht S; Roodt J; Badenhorst P
    J Thromb Haemost; 2009 Mar; 7(3):429-37. PubMed ID: 19207364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.